ES486750A1 - Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilico - Google Patents

Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilico

Info

Publication number
ES486750A1
ES486750A1 ES486750A ES486750A ES486750A1 ES 486750 A1 ES486750 A1 ES 486750A1 ES 486750 A ES486750 A ES 486750A ES 486750 A ES486750 A ES 486750A ES 486750 A1 ES486750 A1 ES 486750A1
Authority
ES
Spain
Prior art keywords
preparation
composition containing
isoxazole derivative
isoxazole
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES486750A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES486750A1 publication Critical patent/ES486750A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para preparar la (4-trifluorometil)-anilida de ácido 5-metilisoxazol-4-carboxílico de la fórmula I **(Fórmula)** la reacción según el procedimiento se realiza convenientemente en un agente de reparto o disolvente, que se comporta de manera indiferente frente a los participantes en la reacción en las condiciones de reacción. Para ello entran en consideración por ejemplo nitrilos, tales como acetonitrilo, éteres, tales como dietiléter, tetrahidrofurano o dioxano y alcoholes, tales como metanol, etanol, propanol o isopropanol y agua.
ES486750A 1978-12-16 1979-12-11 Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilico Expired ES486750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (1)

Publication Number Publication Date
ES486750A1 true ES486750A1 (es) 1980-06-16

Family

ID=6057414

Family Applications (2)

Application Number Title Priority Date Filing Date
ES486758A Expired ES486758A1 (es) 1978-12-16 1979-12-11 Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilicoŸ
ES486750A Expired ES486750A1 (es) 1978-12-16 1979-12-11 Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES486758A Expired ES486758A1 (es) 1978-12-16 1979-12-11 Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilicoŸ

Country Status (25)

Country Link
US (2) US4284786A (es)
EP (1) EP0013376B1 (es)
JP (1) JPS5583767A (es)
AR (2) AR222680A1 (es)
AT (1) ATE1067T1 (es)
AU (1) AU529341B2 (es)
BG (1) BG60764B2 (es)
CA (1) CA1129867A (es)
DE (2) DE2854439A1 (es)
DK (1) DK149886C (es)
EG (1) EG13926A (es)
ES (2) ES486758A1 (es)
FI (1) FI64154C (es)
GR (1) GR72731B (es)
HU (1) HU178015B (es)
IE (1) IE49126B1 (es)
IL (1) IL58951A (es)
LU (1) LU90466I2 (es)
MX (2) MX6174E (es)
NL (1) NL990037I2 (es)
NO (1) NO148925C (es)
NZ (1) NZ192400A (es)
PH (1) PH16627A (es)
PT (1) PT70596A (es)
ZA (1) ZA796793B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ES2124799T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 alfa.
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
TW314467B (es) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
ES2148561T3 (es) * 1994-10-17 2000-10-16 Aventis Pharma Ltd Prevencion y curacion de enfermedades alergicas de tipo i.
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
KR20020067545A (ko) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
WO2001060363A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
SI1381356T1 (sl) 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
CN101242831A (zh) * 2005-08-31 2008-08-13 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
US9073997B2 (en) * 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20230123588A1 (en) 2020-03-06 2023-04-20 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
WO2023152290A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
ES486758A1 (es) 1980-05-16
AR222680A1 (es) 1981-06-15
LU90466I2 (fr) 2000-01-03
PT70596A (de) 1980-01-01
EP0013376A3 (en) 1980-09-17
NO148925B (no) 1983-10-03
IL58951A (en) 1984-01-31
HU178015B (en) 1982-02-28
JPS5583767A (en) 1980-06-24
CA1129867A (en) 1982-08-17
ATE1067T1 (de) 1982-06-15
MX8403A (es) 1994-03-31
AU529341B2 (en) 1983-06-02
US4284786A (en) 1981-08-18
IL58951A0 (en) 1980-03-31
DE2854439A1 (de) 1980-07-03
FI64154B (fi) 1983-06-30
FI793899A (fi) 1980-06-17
MX6174E (es) 1984-12-04
JPH0133470B2 (es) 1989-07-13
AU5385379A (en) 1980-06-19
EP0013376A2 (de) 1980-07-23
NL990037I1 (nl) 2000-01-03
NO148925C (no) 1984-01-11
ZA796793B (en) 1980-11-26
DE2962929D1 (en) 1982-07-08
PH16627A (en) 1983-12-05
IE49126B1 (en) 1985-08-07
NZ192400A (en) 1982-02-23
GR72731B (es) 1983-12-01
EG13926A (en) 1982-09-30
AR226894A1 (es) 1982-08-31
FI64154C (fi) 1983-10-10
BG60764B2 (bg) 1996-02-29
IE792426L (en) 1980-06-16
NO794094L (no) 1980-06-17
DK149886C (da) 1987-04-21
DK534279A (da) 1980-06-17
US4351841A (en) 1982-09-28
DK149886B (da) 1986-10-20
NL990037I2 (nl) 2000-01-03
EP0013376B1 (de) 1982-05-19

Similar Documents

Publication Publication Date Title
ES486750A1 (es) Procedimiento para la preparacion de la (4-trifluorometil)- anilida de acido 5-metilisoxazol-4-carboxilico
JPS5793978A (en) Amides of oxazole and isoxazole
ZA79872B (en) New derivatives of n-phenyl-1,3-oxazolidine-2,4-diones exerting a fungicidal action,and process for preparing same
ES486749A1 (es) Procedimiento para la preparacion de amidas de acidos isoxa-zol-4-carboxilicos
CH614945A5 (en) Process for the preparation of novel 5-methyl-isoxazole-4-carboxylic acid anilides
JPS525751A (en) Process for preparation of (e)-p-(b-substituted-vinyl) phenylacetate
JPS5224506A (en) Tape guide
JPS5223058A (en) Preparation of indanylpropionic acid derivatives
JPS5227331A (en) Execution real time integrator
JPS5211431A (en) Fuel feeding apparatus
JPS51140703A (en) Method of coating
JPS51115924A (en) A herbicide composition
JPS5246494A (en) Cutting machine
JPS525731A (en) Liquid crystal compound and liquid crystal mixture
JPS5266530A (en) Preparation of novel schiff base compounds
JPS5233660A (en) Preparation of (e)-2-)p-(beta-substituted vinyl0 phenyl) aliphati c acids
JPS51134391A (en) Display unit
JPS51120723A (en) Objective lens for deplicating
JPS5230068A (en) Device for controlling supersonic wave
JPS5254545A (en) Pinball device
JPS5294547A (en) Power source device for high-tension heating device
JPS5220075A (en) Temperature measurement device
JPS5359662A (en) Novel acetonitriles and process for preparation of the same
JPS52151139A (en) Novel hydroxamic acids and remedies for lithamgiuria
JPS5384954A (en) Ml-236b carboxylic acid ester and remedies of hyperlipemia containing the same